DNER and head and neck squamous cell carcinoma: As we anticipated based on our previous analysis, the BET inhibitor PLX51107 demonstrated significantly lower GRAOC values in the AT subtype compared to any other HNSCC subtype, indicating an increased resistance to treatment in that group (Figure 3B).